BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Stocks to Buy with Exponential Growth Heading into 2026. On October 27, the company announced financial results for Q3 2025 and highlighted the contributions from its Enzyme Therapies and Skeletal Conditions business units to date this year, thanks to over 20% revenue growth from PALYNZIQ and VOXZOGO. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that its strategic investments in these focused business units continue to generate healthy results, and it expects sustained financial performance from each of these businesses.

Enzyme Therapies and Skeletal Conditions are central to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s growth strategy, apart from the new business development opportunities and its advancing internal pipeline. As the company focuses on the business units aligned with its strategic priorities, it is pursuing options to divest ROCTAVIAN and remove it from the portfolio.

In Q3 2025, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw total revenues of $776 million, reflecting a rise of 4% compared to the same period in 2024. This was helped by healthy revenue growth in VOXZOGO® and PALYNZIQ®, attributable to new patients initiating therapy throughout all regions.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.